An AAV Platform Advancing Successful Viral Vector Based Therapeutics

By Michael Baker, PhD, Senior Director, Viral Gene Therapy

Cell Lab GettyImages-1183901928

Decades of technological innovation and scientific advances have revolutionized the treatment paradigm for many conditions that have long eluded conventional therapies. Advanced viral vector-based therapeutic and immunization strategies, such as gene therapy, oncolytic viruses, and viral vaccines, are at the forefront of these innovative modalities and offer the promise of preventing or slowing the progression of, and perhaps even curing, previously unreachable conditions.

In this article, learn more about addressing substantial challenges in viral vector manufacture and an AAV platform approach that drives rapid and predictable progression of high-quality viral vector products from process development to clinical and commercial supply.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma

FUJIFILM Diosynth Biotechnologies